Fate Therapeutics wins $15 million CIRM grant for FT819 lupus nephritis Phase 2 trial

Bitget2026/09/25 11:01

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Fate Therapeutics won a USD 15 million CLIN2 grant from the California Institute for Regenerative Medicine to advance its RECLAIM-LN trial.
Funding supports Phase 2, potentially registrational testing of FT819 off-the-shelf CAR T-cell therapy in refractory lupus nephritis.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Fate Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609250700PRIMZONEFULLFEED9833804) on September 25, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Fate Therapeutics wins $15 million CIRM grant for FT819 lupus nephritis Phase 2 trial

You may also like

Crypto prices